NZ504870A - Triazolo-pyridazine derivatives as ligands for gaba receptors - Google Patents

Triazolo-pyridazine derivatives as ligands for gaba receptors

Info

Publication number
NZ504870A
NZ504870A NZ504870A NZ50487099A NZ504870A NZ 504870 A NZ504870 A NZ 504870A NZ 504870 A NZ504870 A NZ 504870A NZ 50487099 A NZ50487099 A NZ 50487099A NZ 504870 A NZ504870 A NZ 504870A
Authority
NZ
New Zealand
Prior art keywords
methyl
triazolo
ligands
pyridazine derivatives
gaba receptors
Prior art date
Application number
NZ504870A
Other languages
English (en)
Inventor
Alexander Richard Guiblin
Timothy Harrison
Andrew Madin
Kevin William Moore
Michael Geoffrey Neil Russell
Gayle Scott
Leslie Joseph Street
Ian James Collins
William Robert Carling
Jose Luis Castro Pineiro
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801233.9A external-priority patent/GB9801233D0/en
Priority claimed from GBGB9821517.1A external-priority patent/GB9821517D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NZ504870A publication Critical patent/NZ504870A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NZ504870A 1998-01-21 1999-01-13 Triazolo-pyridazine derivatives as ligands for gaba receptors NZ504870A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801233.9A GB9801233D0 (en) 1998-01-21 1998-01-21 Therapeutic agents
GBGB9821517.1A GB9821517D0 (en) 1998-10-02 1998-10-02 Therapeutic agents
PCT/GB1999/000103 WO1999037644A1 (en) 1998-01-21 1999-01-13 Triazolo-pyridazine derivatives as ligands for gaba receptors

Publications (1)

Publication Number Publication Date
NZ504870A true NZ504870A (en) 2002-11-26

Family

ID=26312988

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504870A NZ504870A (en) 1998-01-21 1999-01-13 Triazolo-pyridazine derivatives as ligands for gaba receptors

Country Status (24)

Country Link
US (2) US6579875B1 (US06828322-20041207-C00025.png)
EP (1) EP1049696A1 (US06828322-20041207-C00025.png)
JP (1) JP2002501066A (US06828322-20041207-C00025.png)
KR (1) KR20010034257A (US06828322-20041207-C00025.png)
CN (1) CN1110498C (US06828322-20041207-C00025.png)
AU (1) AU748737B2 (US06828322-20041207-C00025.png)
BG (1) BG104671A (US06828322-20041207-C00025.png)
BR (1) BR9906905A (US06828322-20041207-C00025.png)
CA (1) CA2315763A1 (US06828322-20041207-C00025.png)
CZ (1) CZ290883B6 (US06828322-20041207-C00025.png)
EA (1) EA002755B1 (US06828322-20041207-C00025.png)
EE (1) EE200000430A (US06828322-20041207-C00025.png)
GE (1) GEP20032868B (US06828322-20041207-C00025.png)
HR (1) HRP20000492A2 (US06828322-20041207-C00025.png)
HU (1) HUP0100575A3 (US06828322-20041207-C00025.png)
IL (1) IL136442A0 (US06828322-20041207-C00025.png)
IS (1) IS5540A (US06828322-20041207-C00025.png)
MX (1) MXPA00007135A (US06828322-20041207-C00025.png)
NO (1) NO315516B1 (US06828322-20041207-C00025.png)
NZ (1) NZ504870A (US06828322-20041207-C00025.png)
PL (1) PL341652A1 (US06828322-20041207-C00025.png)
SK (1) SK10922000A3 (US06828322-20041207-C00025.png)
WO (1) WO1999037644A1 (US06828322-20041207-C00025.png)
YU (1) YU43800A (US06828322-20041207-C00025.png)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2315763A1 (en) * 1998-01-21 1999-07-29 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0017543D0 (en) 2000-07-17 2000-09-06 Merck Sharp & Dohme Therapeutic agents
WO2005058860A1 (ja) * 2003-12-19 2005-06-30 Ube Industries, Ltd. 4−置換又は非置換テトラヒドロピラン−4−カルボン酸化合物又はそのエステル化合物の製法
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EA015754B1 (ru) * 2005-12-21 2011-12-30 Янссен Фармацевтика, Н.В. Триазолопиридазины в качестве модуляторов тирозинкиназы
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2123619A1 (de) 2008-05-20 2009-11-25 Bayer Schering Pharma AG Neue [F-18]-Markierte L-Glutaminsäure-und L-Glutaminderivate (II), ihre Verwendung sowie Verfahren zu ihrer Herstellung
PT2328414E (pt) * 2008-08-29 2014-03-17 Concert Pharmaceuticals Inc Derivados de triazol-piridazina substituídos
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
AU2010276537B2 (en) 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9089531B2 (en) 2010-09-28 2015-07-28 The Regents Of The University Of California GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
NO3175985T3 (US06828322-20041207-C00025.png) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2017151617A1 (en) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
CN107344936B (zh) * 2016-05-06 2022-06-03 上海赛默罗生物科技有限公司 三唑哒嗪类衍生物、其制备方法、药物组合物和用途
JP7305614B2 (ja) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1080712A (en) * 1976-09-22 1980-07-01 Jay D. Albright Hypotensive agents
US4230705A (en) * 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4112095A (en) 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
PH12424A (en) 1976-10-26 1979-02-15 American Cyanamid Co Method of treating anxiety in mammals
US4260755A (en) 1979-10-31 1981-04-07 American Cyanamid Company Novel 6-phenyl and substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines
US4260756A (en) * 1979-11-15 1981-04-07 American Cyanamid Company 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines
FI81350C (fi) 1982-01-18 1990-10-10 Lepetit Spa Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat.
IT1194310B (it) 1983-07-12 1988-09-14 Lepetit Spa Derivati triazolo (3,4-a) ftalazinici 3,6-disostituiti
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
SK9399A3 (en) * 1996-07-25 2000-04-10 Merck Sharp & Dohme Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
CA2315763A1 (en) * 1998-01-21 1999-07-29 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors

Also Published As

Publication number Publication date
CZ290883B6 (cs) 2002-11-13
US6579875B1 (en) 2003-06-17
CN1110498C (zh) 2003-06-04
CN1288465A (zh) 2001-03-21
EA002755B1 (ru) 2002-08-29
EA200000783A1 (ru) 2000-12-25
HRP20000492A2 (en) 2000-12-31
EE200000430A (et) 2001-12-17
PL341652A1 (en) 2001-04-23
EP1049696A1 (en) 2000-11-08
IS5540A (is) 2000-06-16
WO1999037644A1 (en) 1999-07-29
HUP0100575A2 (hu) 2001-09-28
CZ20002691A3 (cs) 2000-12-13
BR9906905A (pt) 2000-10-10
US20040063714A1 (en) 2004-04-01
NO315516B1 (no) 2003-09-15
HUP0100575A3 (en) 2003-03-28
KR20010034257A (ko) 2001-04-25
US6828322B2 (en) 2004-12-07
CA2315763A1 (en) 1999-07-29
IL136442A0 (en) 2001-06-14
AU748737B2 (en) 2002-06-13
NO20003730L (no) 2000-09-20
NO20003730D0 (no) 2000-07-20
GEP20032868B (en) 2003-01-27
JP2002501066A (ja) 2002-01-15
YU43800A (sh) 2002-12-10
MXPA00007135A (es) 2002-11-07
AU2065799A (en) 1999-08-09
SK10922000A3 (sk) 2001-03-12
BG104671A (en) 2001-05-31

Similar Documents

Publication Publication Date Title
NZ504870A (en) Triazolo-pyridazine derivatives as ligands for gaba receptors
HUP0303350A2 (hu) Szubsztituált imidazo[1,2-a]piridin-, imidazo[1,2-a]pirimidin- és imidazo[1,2-a] pirazin-3-il-amin származékok alkalmazása NOS-inhibitor gyógyszerkészítmények előállítására
MY133209A (en) Chemical compounds
ES2179551T3 (es) Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn.
DE69309670D1 (de) Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
MY141853A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
DE69520360T2 (de) Phosphonsäure verbindungen imre herstellung und verwendung
AR005462A1 (es) Un proceso para preparar ciertos ciclohexapeptidos y compuestos obtenidos mediante dicho procedimiento.
HUP0401086A2 (hu) 4-[(Fenil-piperazinil)-metil]-benzamid-származékok és alkalmazásuk fájdalom, szorongás vagy gasztrointesztinális zavarok kezelésére szolgáló gyógyszerkészítmények előállítására és eljárás a vegyületek előállítására
SE9100342D0 (sv) Novel steroid esters
ATE399753T1 (de) Amide als pyruvatdehydrogenaseinhibitoren
CL2004001167A1 (es) Compuestos derivados de tiazolidindionas; procedimiento de elaboracion: composicion farmaceutica que los contiene; y su uso en el tratamiento de la diabetes.
RU94037235A (ru) Ингибитор фиброза матки
CA2056421A1 (en) Agent against autoimmune diseases
RU94036771A (ru) Ингибиторы ангиогенеза и ангиогенных заболеваний
GB0305575D0 (en) Novel compounds
DE69227583T2 (de) Arylmorpholine, herstellung und verwendung
KR930019690A (ko) 베타-아미노산의 신규 유도체
ES2145260T3 (es) Mejoras introducidas en sintesis quirales.
PE60096A1 (es) Inhibidor de la escualeno sintetasa
MY144338A (en) Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction
WO1994019025A3 (en) Contrast agents
DE69422629D1 (en) Indolderivate als 5-alpha-reductase-1 inhibitoren
RU2006134614A (ru) Производное кумарина и его применение

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)